Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Published

Journal Article

INTRODUCTION: High relapse rates and infections remain primary causes of failure in nonmyeloablative transplantation. Interleukin-2 (IL-2) may stimulate the immune system and improve outcomes. The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant. METHODS: Patients received T-cell-depleted nonmyeloablative transplant from a matched or mismatched related donor. Those with allogeneic engraftment,

Full Text

Duke Authors

Cited Authors

  • Rizzieri, DA; Crout, C; Storms, R; Golob, J; Long, GD; Gasparetto, C; Sullivan, KM; Horwitz, M; Chute, J; Lagoo, AS; Morris, A; Beaven, A; Yang, Y; Peterson, B; Li, Z; Chao, NJ

Published Date

  • January 2011

Published In

Volume / Issue

  • 29 / 1

Start / End Page

  • 56 - 61

PubMed ID

  • 21166499

Pubmed Central ID

  • 21166499

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

Digital Object Identifier (DOI)

  • 10.3109/07357907.2010.535055

Language

  • eng

Conference Location

  • England